Tarsus Pharmaceuticals (NasdaqGS:TARS) FY Conference Transcript

Tarsus Pharmaceuticals FY Conference Summary Company Overview - Company Name: Tarsus Pharmaceuticals - Ticker: NasdaqGS:TARS - Headquarters: Irvine, California - Product: XDEMVY for the treatment of Demodex blepharitis, a prevalent eye disease caused by Demodex mites [4][5] Financial Performance - 2023 Approval: XDEMVY was approved in August 2023 [4] - 2023 Revenue: Approximately $450 million, treating about 500,000 patients [4] - Market Potential: 25 million patients affected by Demodex blepharitis; 9 million are immediately addressable [5][24] - 2026 Revenue Guidance: Expected top-line revenue between $690 million and $700 million [5] - Long-term Peak Sales Potential: Estimated at around $2 billion [5][35] Market Dynamics - Market Education: Tarsus has created a new category for Demodex blepharitis, previously unfamiliar to many doctors [10] - Payer Coverage: Achieved 90% prior payer coverage, with a gross to net discount of about 44% [12][13] - Sales Force Expansion: Started with a 100-person sales force, increased by 50% within the first year, and added 15-20 key account leaders recently [15][16] Prescriber Engagement - Current Prescribers: Over 20,000 prescribers, with 15,000 responsible for 85% of prescriptions [17] - Utilization Growth: 40% of prescribers write prescriptions weekly; daily prescribers have increased by 20% since the last quarter [18][19] Direct-to-Consumer (DTC) Campaign - Campaign Launch: Initiated last year, combining targeted streaming and network TV ads [21][22] - Impact: Increased awareness, with one in four patients now asking for XDEMVY by name [25] Seasonal Trends and Guidance - Q1 Trends: Typically sees a drop in prescriptions due to deductible resets; expected recovery in Q2 [28][31] - Growth Expectations: Anticipated 50%+ growth for 2026, with a stable payer base and historical data to support guidance [26][27] Pipeline Development - Ocular Rosacea Program: Phase II study initiated for a sterile gel formulation targeting ocular rosacea, with results expected in the first half of next year [38][39] - Lyme Disease Prevention: Phase II study for an oral tablet targeting Lyme disease, with data expected in the first half of next year [40] Financial Position - Balance Sheet Strength: Over $400 million in cash and equivalents, minimal debt, and nearing profitability [41] Market Perception and Stock Response - Investor Sentiment: Skepticism regarding the disease's awareness and the stock's response to script trends; viewed as a buying opportunity given strong guidance [43][44] Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with a strong product offering, expanding market presence, and a robust pipeline, while navigating investor perceptions and market dynamics effectively.